Pharmahungary Group

Pharmahungary Group is a European contract research organization (CRO) headquartered in Budapest, Hungary, that provides preclinical and clinical research and development services to pharmaceutical, biotechnology, and medical device companies as well as academic and university research groups worldwide. According to its official website, the company has been advancing drug, medical device, and Advanced Therapy Medicinal Product development projects since 2001, and describes itself as combining scientific excellence with regulatory expertise to bridge the gap between laboratory discoveries and clinical applications. The company's preclinical R&D services cover the full range of efficacy studies from cells to large animal models, with a focus on cardiovascular, metabolic, renal, inflammation, musculoskeletal, and oncology indications. Its clinical R&D services include end-to-end support for medical device and in vitro diagnostic trials, investigator-initiated trials (IITs), and niche trials involving sensitive patient populations, along with regulatory and ethics committee support and registration assistance. Pharmahungary positions itself as a scientifically driven CRO with a strong publication record. Its website states that its team includes highly cited researchers, pharmacologists, and bioinformatics experts, and cites over 430 scientific publications, impact factors over 1,600, and more than 31,000 citations. The company reports over 24 years of experience in drug and medical device development with over 350 development projects completed. The firm operates primarily from Hungary and serves clients across Europe and worldwide, with clinical trial support in Central Europe aligned with the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). It is a private company and is not publicly listed.

Pharmahungary Group is a European contract research organization based in Budapest, Hungary. According to its official website, the company has been advancing drug, medical device, and Advanced Therapy Medicinal Product development projects since 2001. Over more than two decades it has built a track record of over 350 completed development projects in preclinical and clinical R&D collaborations. The company's stated mission is to provide a wide range of innovative and cost-effective preclinical pharmacology R&D services focusing on cardiovascular, metabolic, renal, inflammation, musculoskeletal, and oncology indications, with strong scientific support. It also provides clinical R&D services covering full management of clinical trials with medical devices, Advanced Therapeutic Medicinal Products, Investigator Initiated Trials, and clinical trials that need strong regulatory and scientific support, such as those involving sensitive patient populations. In addition, Pharmahungary manages internal R&D projects to develop new technologies for out-licensing and co-development in the fields of diagnosis and therapy of cardiovascular and metabolic disease. Pharmahungary describes itself as combining scientific excellence with regulatory expertise to support pharma, biotech, and medical device companies as well as academic and university research groups worldwide. Its team includes highly cited researchers, pharmacologists, and bioinformatics experts. The company reports over 430 scientific publications, impact factors over 1,600, and more than 31,000 citations, and states that it has over 24 years of experience in drug and medical device development. Its preclinical services span from cells to large animal models, covering disease models in cardiovascular (myocardial infarction, heart failure, arrhythmias), metabolic (diabetes, insulin resistance, hyperlipidemia, atherosclerosis, obesity, NAFLD, NASH), renal (uremia, acute pancreatitis), inflammation (sepsis, septic shock, chronic arthritis, traumatic neuropathy, allergic contact dermatitis, ulcerative colitis, acute interstitial pneumonitis, psoriasiform dermatitis), oncology (triple negative breast cancer, small cell lung cancer), and musculoskeletal (sarcopenia) areas. The company also offers in vitro, in vivo, ex vivo models, bioinformatics analysis, and custom combined disease animal models. On the clinical side, Pharmahungary provides end-to-end support for medical device and in vitro diagnostic research, investigator-initiated trials, and niche trials, with regulatory compliance through expert guidance. It supports clinical trials in Central Europe according to the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), offering full regulatory support, patient safety oversight, serious adverse event reporting, and clinical monitoring as per Good Clinical Practice (GCP). It also assists with regulatory submissions, ethics committee documentation, protocol development, country-specific patient information leaflets and informed consent forms, and clinical trial and product registration. The company is headquartered in Budapest, Hungary, and operates as a private entity. It serves clients worldwide, with a particular focus on European and Central European markets.

• 2001

  Pharmahungary begins advancing drug, medical device, and Advanced Therapy Medicinal Product development projects.

• Company reports over 350 completed development projects in preclinical and clinical R&D collaborations.

• Company reports over 430 scientific publications, impact factors over 1,600, and more than 31,000 citations.

Innovative, cost-effective, flexible, high-quality preclinical and clinical R&D services backed by international scientific excellence and regulatory expertise.

• Preclinical R&D Services

  Efficacy studies from cells to large animal models focusing on cardiovascular, metabolic, renal, inflammation, musculoskeletal, and oncology indications.

• Clinical R&D Services

  End-to-end support for medical device and IVD trials, investigator-initiated trials, and niche trials, including regulatory and ethics committee support.

• Cardiovascular Platform

  Cardiovascular models from cells to large animals including myocardial infarction, heart failure, and arrhythmia disease models.

• Metabolic Platform

  In vivo models of metabolic diseases such as diabetes, hyperlipidemia, atherosclerosis, obesity, NAFLD, and NASH.

1. 1Preclinical & Clinical Research Services | Pharmahungarypharmahungary.com
2. 2Pharma CRO Hungary – About uspharmahungary.com
3. 3Preclinical & Clinical R&D Services | Pharmahungarypharmahungary.com
4. 4Clinical R&D Services for Studies | PharmaHungarypharmahungary.com
5. 5Pharmahungary Group (Hungary) - Wikidatawikidata.org